Seqens Seqens

X
[{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Gummy Company Secures The First (IND) Gummy Drug Approval From FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SWEET REMEDY Gummies with Libido-Boosting Drug Being Hailed as Bedroom Flop Stoppers \u2013 with Effects in Just Minutes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Seattle Gummy

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Sweet Remedy (tadalafil) gummy is a PDE5 inhibitor, small molecule drug. It is being evaluated in phase 1 clinical trials for the treatment of patients with erectile dysfunction.

            Lead Product(s): Tadalafil

            Therapeutic Area: Psychiatry/Psychology Product Name: Sweet Remedy

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SGC scientists have developed a suite of technologies that enable the incorporation of various drug compounds into a novel gummy matrix, thus solving drug solubility, stability, and taste issues.

            Lead Product(s): Cetirizine Dihydrochloride

            Therapeutic Area: Immunology Product Name: Ceteric Allergy Gummy

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY